Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics, Inc. (Nasdaq: AKRO) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. This news page aggregates company announcements, clinical updates and financial disclosures so readers can follow how Akero’s development programs progress over time.
Akero’s news flow is heavily driven by data from its clinical trials. Regular press releases cover results and analyses from the Phase 2b HARMONY and SYMMETRY studies, which evaluate EFX in patients with pre-cirrhotic (F2–F3) MASH and compensated cirrhosis (F4) due to MASH, respectively. Updates often include histology outcomes, non-invasive fibrosis markers, and AI-based digital pathology findings that the company uses to characterize the antifibrotic activity of EFX.
Investors and clinicians can also find announcements related to the global Phase 3 SYNCHRONY program, including enrollment milestones and planned timing of readouts for SYNCHRONY Histology, SYNCHRONY Outcomes and SYNCHRONY Real-World. In addition, Akero regularly reports quarterly financial results, business updates, and participation in major healthcare and liver disease conferences, where management presents new data and analyses.
Another key category of news involves corporate and strategic developments. Akero has announced an Agreement and Plan of Merger under which it is expected to become a wholly owned subsidiary of Novo Nordisk A/S, subject to stockholder and regulatory approvals. Readers who follow AKRO news can track updates on this proposed transaction alongside ongoing clinical and scientific disclosures. Bookmark this page to quickly access the latest company-issued information, from peer-reviewed publication announcements to conference presentations and regulatory-related communications.
Akero Therapeutics (Nasdaq: AKRO) reported second quarter 2020 results, showcasing significant histological improvements in non-alcoholic steatohepatitis (NASH) patients treated with efruxifermin (EFX). After 16 weeks, 48% of patients saw at least one-stage fibrosis improvement. Additionally, EFX demonstrated reductions in liver fat and improvements in glycemic control and body weight. The company raised approximately $216.4 million through a public offering. Cash equivalents stand at $305.6 million post-offering, supporting its ongoing clinical trials and research programs.
On July 21, 2020, Akero Therapeutics (Nasdaq: AKRO) announced the publication of Phase 1 clinical trial data for efruxifermin (EFX) in Cell Reports Medicine. The study indicates EFX significantly improves insulin sensitivity and lipid metabolism in type 2 diabetes patients with a half-life of 3-3.5 days, enabling weekly dosing. Akero's CEO highlighted that EFX met all endpoints in the Phase 2a BALANCED study, showing the largest reductions in liver fat and histological improvements to date, suggesting a promising clinical profile for treating non-alcoholic steatohepatitis (NASH).
Akero Therapeutics (Nasdaq: AKRO) announced the pricing of an underwritten public offering of 5,228,166 shares of common stock at $36.00 per share, expected to raise approximately $188.2 million before expenses. A 30-day option is granted to underwriters for an additional 784,224 shares. The offering is anticipated to close on July 10, 2020, subject to customary conditions. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore are the joint managers for this offering. The company aims to support its mission of developing therapies for non-alcoholic steatohepatitis (NASH).
Akero Therapeutics (Nasdaq: AKRO) has initiated an underwritten public offering of 4,750,000 shares of its common stock, with the possibility of an additional 712,500 shares available to underwriters. This offering is aimed at strengthening its financial position to support the development of treatments for non-alcoholic steatohepatitis (NASH). J.P. Morgan Securities, Morgan Stanley, Jefferies, and Evercore are serving as joint book-running managers. The offering's completion is subject to market conditions and regulatory approval.
Akero Therapeutics (Nasdaq: AKRO) announced plans to discuss new efficacy and safety data from its Phase 2a BALANCED study of AKR-001 for patients with nonalcoholic steatohepatitis (NASH). The results, including biopsy data, will be shared during a conference call and webcast on June 30, 2020, at 4:30 p.m. ET. Akero aims to address the growing NASH epidemic by developing innovative treatments, with AKR-001 as their lead candidate currently in clinical trials.
Akero Therapeutics (Nasdaq: AKRO) announced the dosing of the first subject in Cohort C of its Phase 2a BALANCED trial for NASH, targeting 30 patients with compensated cirrhosis. This expansion aims to assess the safety and tolerability of AKR-001, designed to alleviate liver fat and inflammation. Prior trial results indicated promising efficacy in reducing liver fat. NASH affects 17 million Americans, posing significant health risks. The primary aim is to evaluate AKR-001's potential to delay liver disease progression.